OSLO, NORWAY, Sept. 5, 2022 /PRNewswire/ — Lytix biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today announces the appointment of Stephen Worsley as Chief Business Officer (CBO).
Stephen Worsley is a pharmaceutical executive with over 25 years of experience in business development leadership and executing highly rated strategic deals in impact-enhancing roles in the biopharmaceutical and drug discovery/development markets. . As a business development executive, Worsley has led negotiations for innovative, award-winning technology and product partnerships with leading therapeutics companies.
Most recently, Stephen Worsley served as Vice President of Strategic Business Development at Redwood Biosciences/Catalent Pharma Services. Prior to that, he held positions such as He was CBO of Sutro Biopharma, He was Senior Vice President of Business Development of IndiMolecular, He was President and Vice President of Business Development of Peregrine Pharmaceutical (dba Avid Pharma Services).
“We are pleased to welcome Stephen Worsley to the management team of Lytix Biopharma as we plan continued progress in Lytix’s development program to reach several important milestones. “ Lytix CEO Øystein Rekdal said: “His extensive experience in business development, having led various strategic partnerships, acquisitions, equity investments, clinical partnerships and licensing transactions, will advance our exciting pipeline of immunostimulants against cancer through further clinical development. There are several potential partnership opportunities on the way to market.”
Stephen will assume the Lytix leadership position on September 6th. With his position as CBO, he will join his Lytix executive management team.
“I am very pleased to join the Lytix team at an exciting time for us as we develop a highly promising new class of immunostimulants for the treatment of cancer.Stephen Worsley said.Increased interest in the platform and evolving clinical results will allow Lytix to explore several value-creating business development opportunities over the coming months and years..”
For more information, please contact:
Ole Peter Nordby, firstname.lastname@example.org
This information was provided by Cision http://news.cision.com.
View Original Content: https://www.prnewswire.com/news-releases/lytix-biopharma-appoints-stephen-worsley-as-chief-business-officer-301617678.html
Source: Lytix Biopharma AS
Company code: Oslo: LYTIX